Early Alzheimer's Disease Clinical Trial
Official title:
A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients With Early Alzheimer's Disease (Hetero/Homozygote APOE4 Carriers)
A Phase 2a study in men and women with early Alzheimer's disease to evaluate the pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.
This study will be a proof of concept, Phase 2a study in patients with early Alzheimer's disease (clinical diagnosis of Alzheimer's disease Stage 3 or 4 based on the National Institute on Aging Alzheimer's Association Research Framework criteria) to evaluate the Pharmacodynamic, cognitive effects, Pharmacokinetic, and safety and tolerability of obicetrapib therapy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04693520 -
Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
|
Phase 2 | |
Recruiting |
NCT05122598 -
Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease
|
Phase 2 | |
Active, not recruiting |
NCT04770220 -
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
|
Phase 3 | |
Active, not recruiting |
NCT04777396 -
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
|
Phase 3 | |
Active, not recruiting |
NCT03887455 -
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
|
Phase 3 | |
Recruiting |
NCT05531656 -
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
|
Phase 2 | |
Recruiting |
NCT04599764 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease
|
N/A | |
Completed |
NCT02859207 -
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
|
Phase 1 | |
Enrolling by invitation |
NCT06304883 -
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
|
Phase 3 |